JHL Biotech Inc., of Hsinchu, Taiwan, said it submitted a phase I clinical trial application to European authorities for its proposed bevacizumab biosimilar, JHL-1149. The company is planning to conduct a single-site, three-arm pharmacokinetic study in healthy volunteers in Sofia, Bulgaria, beginning March 2018.